AusperBio

AusperBio announced $120M in Series C financing on August 27, 2026. AusperBio closed a $120 million Series C led by a strategic investor, with new investor RA Capital participating, to advance its hepatitis B candidate AHB-137.

Round details

The financing includes backing from RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, CDH Investments. The company did not publish a valuation with the announcement.

• Round: Series C
• Capital announced: $120M
• Total funding reported: $360M

How the company plans to use the capital

AusperBio said the financing will support continued development of AHB-137, including its Phase 3 registrational program and commercialization readiness. Proceeds will also accelerate AHB-171, advance next-generation combination approaches for chronic hepatitis B, and further expand the company’s pipeline.

Why this matters for GTM teams

AusperBio describes itself as a near-commercial company with an initial focus on achieving a functional cure for chronic hepatitis B, and said existing investors continued their support in the round.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: AusperBio Series C announcement.